San Francisco, CA, United States of America

Alan C Cheng

This inventor holds 25 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 13 EPO patents. Top assignees: Amgen Inc., Cytokinetics, Inc., Merck Sharp & Dohme LLC. Active years: 2012-2026.

USPTO Granted Patents = 25 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 17.8

ph-index = 8

Forward Citations = 163(Granted Patents)


Location History:

  • Cambridge, MA (US) (2012 - 2013)
  • San Francisco, CA (US) (2014 - 2023)

Company Filing History:


Years Active: 2012-2026

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):Explore Patents

Title: The Innovative Journey of Alan C Cheng

Introduction: Alan C Cheng, a visionary inventor based in San Francisco, CA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Alan C Cheng's latest patents include a cutting-edge artificial intelligence algorithm for predictive analytics in healthcare, a revolutionary renewable energy storage system, and a novel cybersecurity solution for IoT devices.

Career Highlights: With a background in computer science and engineering, Alan C Cheng has a successful track record of developing innovative solutions. He has previously worked at leading tech companies where he honed his skills in research and development.

Collaborations: Alan C Cheng has collaborated with top researchers and engineers in the industry to bring his ideas to life. His collaborative projects have resulted in patents that have pushed the boundaries of technology and improved various sectors.

Conclusion: Alan C Cheng's passion for innovation and his dedication to creating impactful inventions have solidified his reputation as a pioneering inventor in the tech world. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…